간염 치료제 시장 : 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2024-2032년)

The Global Hepatitis Treatment Market reached a valuation of USD 22.2 billion in 2023 and is expected to grow at a CAGR of 3.5% through the forecast period. The market is primarily driven by the rising incidence of hepatitis B and C infections and the growing global awareness surrounding these conditions. Innovations in treatment options, such as antiviral therapies and immunotherapies, are enhancing patient care and contributing to market expansion. Additionally, advancements in diagnostic technologies like polymerase chain reaction (PCR) testing have improved early detection, further fueling demand for hepatitis treatments.

The overall hepatitis treatment industry is segregated based on Disease Type, Treatment Type, Route of Administration, End-user, and Region.

The market is segmented based on disease type, treatment type, route of administration, and end-user. Among disease types, the hepatitis C segment dominated with USD 9.8 billion in 2023. Rising infection rates and advancements in antiviral treatments are propelling the growth of this segment. Pharmaceutical companies are heavily investing in R&D to enhance drug efficacy, reduce treatment durations, and minimize side effects.

In terms of treatment types, antiviral drugs captured a major share of 61.4% in 2023, driven by the growing prevalence of hepatitis infections. These therapies are crucial in managing hepatitis, particularly for types B and C, where they decrease the viral load and control disease progression. The demand for antiviral drugs is also increasing in emerging markets due to rising awareness of the disease and the importance of early diagnosis.

Regarding the route of administration, the oral segment is set to reach USD 12.1 billion by 2032, thanks to its convenience and high patient compliance. Oral therapeutics, especially direct-acting antivirals, have revolutionized hepatitis treatment with higher efficacy and fewer side effects.

In the end-user category, healthcare providers, including hospitals and specialty clinics, are expected to grow at a CAGR of 3.5%. These providers play a key role in administering antiviral therapies, conducting diagnostics, and monitoring patient progress. Public health initiatives, such as vaccination programs and harm reduction services, also contribute to this segment's growth.

Regionally, North America is projected to reach USD 13.4 billion by 2032, driven by advancements in antiviral therapies and a strong healthcare infrastructure. Europe, particularly the UK, is experiencing robust growth due to rising hepatitis cases and evolving treatment options. In Asia-Pacific, the market is expected to expand at a CAGR of 4.1%, supported by early detection, access to affordable therapies, and government-led hepatitis management programs.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of hepatitis infections
    • 3.2.1.2 Advancements in drug development
    • 3.2.1.3 Rising demand for combination therapies
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of medications
    • 3.2.2.2 Side effects and adverse reactions
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Future market trends
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Hepatitis A
• 5.3 Hepatitis B
• 5.4 Hepatitis C
• 5.5 Other hepatitis types

Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Anti-viral drugs
  • 6.2.1 Nucleoside/nucleotide analogues
  • 6.2.2 Polymerase inhibitors
  • 6.2.3 Protease inhibitors
  • 6.2.4 Other anti-viral drugs
• 6.3 Immune modulators (interferons)
• 6.4 Combination therapies
• 6.5 Liver transplant
• 6.6 Other treatment types

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Parenteral

Chapter 8 Market Estimates and Forecast, By End-user, 2021-2032 ($ Mn)

• 8.1 Key trends
• 8.2 Healthcare providers
  • 8.2.1 Hospitals
  • 8.2.2 Specialty clinics
• 8.3 Patients
• 8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Service Provider
  • 10.1.1 Barnes-Jewish Hospital
  • 10.1.2 Bumrungrad International Hospital
  • 10.1.3 Cedars-Sinai
  • 10.1.4 Cleveland Clinic
  • 10.1.5 Mayo Clinic
• 10.2 Medication Manufacturers
  • 10.2.1 AbbVie Inc.
  • 10.2.2 Biocon, Inc.
  • 10.2.3 Bristol-Myers Squibb Company
  • 10.2.4 Dynavax Technologies
  • 10.2.5 F. Hoffmann-La Roche Ltd.
  • 10.2.6 Gilead Sciences, Inc.
  • 10.2.7 GlaxoSmithKline plc
  • 10.2.8 Lupin Limited
  • 10.2.9 Merck and Co., Inc.
  • 10.2.10 Novartis AG